Cinpanemab Explained
| Type: | mab |
| Target: | α-Synuclein |
| Cas Number: | 2094516-02-4 |
| Drugbank: | DB16127 |
| Unii: | W83JGQ40XX |
| Synonyms: | BIIB054; BIIB-054; NI-202; NI202 |
Cinpanemab (; developmental code names BIIB054, NI-202) is an anti-α-synuclein drug acting as a monoclonal antibody against α-synuclein which was under development for the treatment of Parkinson's disease.[1] [2] It showed no significant influence on disease progression in a 52-week phase 2 clinical trial. The drug reached phase 2 clinical trials but was discontinued in 2021 due its lack of effectiveness.[3] It was under development by Biogen.
See also
External links
Notes and References
- Web site: Cinpanemab . AdisInsight . Springer Nature Switzerland AG . 4 June 2021 . 26 September 2024.
- Baggett D, Olson A, Parmar MS . Novel Approaches Targeting in α-Synuclein for Parkinson's Disease: Current Progress and Future Directions for the Disease-Modifying Therapies . Brain Disorders . Elsevier BV . 2024 . 16 . 2666-4593 . 10.1016/j.dscb.2024.100163 . 100163.
- Lang AE, Siderowf AD, Macklin EA, Poewe W, Brooks DJ, Fernandez HH, Rascol O, Giladi N, Stocchi F, Tanner CM, Postuma RB, Simon DK, Tolosa E, Mollenhauer B, Cedarbaum JM, Fraser K, Xiao J, Evans KC, Graham DL, Sapir I, Inra J, Hutchison RM, Yang M, Fox T, Budd Haeberlein S, Dam T . Trial of Cinpanemab in Early Parkinson's Disease . N Engl J Med . 387 . 5 . 408–420 . August 2022 . 35921450 . 10.1056/NEJMoa2203395 .
